Literature DB >> 8241347

High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction.

K Ihnken1, W Speiser, W Ruf, W Thiel, M Schlepper, G Müller-Berghaus.   

Abstract

The fibrinolytic capacity of blood depends mainly on the amount of tissue-type plasminogen activator (t-PA) activity and plasminogen activator inhibitor type-1 (PAI-1) activity. Previous studies linked high PAI activity or low t-PA activity with the development of atherosclerosis and thromboembolic diseases. Yet, there are conflicting reports in the literature as to whether there is higher PAI activity in patients with myocardial infarction (MI) than in patients with coronary artery disease (CAD) without previous MI. In this retrospective study, t-PA activity, t-PA antigen, and PAI activity before and after a venous occlusion test (VOT) of 10 min were assessed in 109 patients with angiographically documented CAD, in two subgroups of CAD patients with (n = 66) or without (n = 43) previous MI, and in subgroups of CAD patients according to their triglyceride levels and other risk factors. The mean values of t-PA activity in the whole patient group showed a 100-fold increase and a 3.1-fold increase in t-PA antigen after VOT (0.03 +/- 0.03 to 3.0 +/- 6.8 U/ml and 16.5 +/- 6.9 to 51.0 +/- 25.4 ng/ml, p < 0.05). PAI activity was 24.4 +/- 11.0 before and 19.6 +/- 13.2 U/ml after VOT. Within the CAD group, no difference was found between patients without MI and survivors of previous MI in PAI activity before VOT (24.6 +/- 10.7 vs. 24.3 +/- 11.3 U/ml) and after VOT (19.0 +/- 12.1 vs 20.0 +/- 14.0 U/ml), or t-PA activity before (0.03 +/- 0.01 vs. 0.04 +/- 0.04 U/ml) and after VOT (2.8 +/- 7.0 vs. 3.2 +/- 6.7 U/ml). In 39.4% of CAD patients elevated plasma PAI activity before VOT (> 25 U/ml) was found. This subgroup of patients represented the highest PAI activity after VOT (p < 0.05), the lowest t-PA activity after VOT (p < 0.001), and the highest triglyceride levels (p < 0.05). In 11% of the patients, a small increase in t-PA activity (less than 0.5 U/ml) after VOT was seen. This group showed the lowest t-PA antigen after VOT (p < 0.001) and the highest fibrinogen level (p < 0.05). Both subgroups showed the same distribution among patients with and without MI. CAD patients with triglyceride levels over 200 mg/dl had the highest PAI activity values before VOT (28.3 +/- 11.8 U/ml; p < 0.01) and after VOT (24.9 +/- 13.2 U/ml; p < 0.01), resulting in low t-PA activity after VOT (p < 0.01).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241347     DOI: 10.1007/bf01715054

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  44 in total

1.  Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis.

Authors:  K Huber; I Resch; T Stefenelli; I Lang; P Probst; F Kaindl; B R Binder
Journal:  Thromb Haemost       Date:  1990-06-28       Impact factor: 5.249

2.  Fibrinolytic activity and coronary-artery disease.

Authors:  R Chakrabarti; E D Hocking; G R Fearnley; R D Mann; T N Attwell; D Jackson
Journal:  Lancet       Date:  1968-05-11       Impact factor: 79.321

Review 3.  Fibrinolysis and atherosclerosis.

Authors:  D Collen; I Juhan-Vague
Journal:  Semin Thromb Hemost       Date:  1988-04       Impact factor: 4.180

4.  Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.

Authors:  A Rydzewski; K Sakata; A Kobayashi; N Yamazaki; T Urano; Y Takada; A Takada
Journal:  Haemostasis       Date:  1990

5.  Activation of coagulation and fibrinolysis in patients with arteriosclerosis: relation to localization of vessel disease and risk factors.

Authors:  W Speiser; P Speiser; E Minar; C Korninger; H Niessner; K Huber; G Schernthaner; H Ehringer; K Lechner
Journal:  Thromb Res       Date:  1990-07-01       Impact factor: 3.944

6.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

7.  Plasminogen activator inhibitor activity as a possible indicator of disease activity in rest angina with angiographically insignificant coronary artery stenosis.

Authors:  K Sakata; C Kurata; A Kobayashi; A Rydzewski; N Yamazaki
Journal:  Thromb Res       Date:  1991-09-01       Impact factor: 3.944

8.  A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall.

Authors:  L Johansson; U Hedner; I M Nilsson
Journal:  Acta Med Scand       Date:  1978

9.  Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.

Authors:  K Huber; D Rosc; I Resch; E Schuster; D H Glogar; F Kaindl; B R Binder
Journal:  Thromb Haemost       Date:  1988-12-22       Impact factor: 5.249

10.  Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.

Authors:  B O Olofsson; G Dahlén; T K Nilsson
Journal:  Eur Heart J       Date:  1989-01       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.